Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 493 full-time employees. The company went IPO on 2019-11-07. The firm focuses on rare diseases, transforming clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The firm's platform includes epidemiological, phenotypic, and genetic data reflecting a global population, as well as a biobank of blood samples from these patients. The firm's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The firm's Clinical Diagnostics segment provides targeted genetic sequencing and diagnostic services to patients through its distribution partners and customers, which are typically physicians, laboratories or hospitals.
9 analistin CNTGF hissesine verdiği değerlendirme temel alınarak Nov 01, 2024 tarihinde güncellenmiştir.
Strong Buy
Strong buy
3
Buy
5
Hold
1
Sell
0
Strong sell
0
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for CNTGF. Our analysts highlight strong fundamentals and favorable market sentiment, positioning CNTGF for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: CNTGF is a Strong Buy candidate.
CNTGF stock price ended at $0.11 on Cuma, after dropping 8.33%
On the latest trading day Mar 20, 2026, the stock price of CNTGF fell by 8.33%, dropping from $0.11 to $0.11. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.11 and a high of $0.11. On the latest trading day, the trading volume for CNTGF rose by 650 shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 810 shares were traded, with a market value of approximately $3.0M.
CNTGFTeknik Sinyalleri
Teknik Sinyaller Özeti
Satın Alma Sinyalleri 3
Nötr Sinyaller 2
Satış Sinyalleri 2
Strong Sell
Sell
Neutral
Buy
Strong Buy
CNTGF, şu anda 3 alım sinyali ve 2 satım sinyali vermektedir. Hisse senedi 12:00 AM'ten beri Aşağı yönlü trend durumundadır ve bu dönemde toplam -8.33% fiyat değişimi gerçekleşti. Genel olarak teknik göstergeler orta vadeli olarak Buy görünüm işaret etmektedir.
CNTGF için Boğa/Ayı Sinyalleri
Hareketli ortalamalar, RSI, MACD ve işlem hacmi gibi temel göstergeleri analiz ederek CNTGF için yükseliş ve düşüş sinyalleri üretiyoruz. Bu analizlerle daha bilinçli yatırım kararları verin.
Takip Soruları
Teknik analiz göstergeleri CNTGF için nasıl uygulanır?
Teknik analize göre, Crown LiquidationCo NV in liquidatie Buy toplam sinyaline sahiptir. Crown LiquidationCo NV in liquidatie 3 adet al sinyali, 2 adet nötr sinyal ve 2 adet sat sinyali vardır.
CNTGF için Fibonacci geri dönüş seviyeleri nelerdir?
Crown LiquidationCo NV in liquidatie için Fibonacci geri dönüş seviyesi 0% ve 23.6% arasındadir。
Crown LiquidationCo NV in liquidatie için RSI nedir?
Crown LiquidationCo NV in liquidatie için mevcut RSI 45.88 'dir, bu da nötr durumunu gösterir
Önümüzdeki 12 ay için Crown LiquidationCo NV in liquidatie fiyatı nedir?
Crown LiquidationCo NV in liquidatie CNTGF önümüzdeki 12 ay için $0 olarak tahmin edilmektedir.
Crown LiquidationCo NV in liquidatie ne kadar yükselmesi bekleniyor?
Wall Street analistlerine göre, Crown LiquidationCo NV in liquidatie $0 yüksek tahminine ulaşması beklenmektedir.